Oct 20, 2026 · 1h 5m
Longevity science tests whether aging can become treatable
209. Dr. David Barzilai: Can We Reverse Aging? Harvard's Latest Longevity Science Explained
The episode separates credible geroscience from longevity hype while showing which interventions remain reliable before experimental therapies mature.
- 1Geroscience treats aging as an interconnected biological process that may be modified rather than a collection of isolated diseases.
- 2Biological-age clocks could help measure risk and treatment effects, but researchers still face challenges defining and validating aging itself.
- 3Exercise, strength, cardiovascular fitness, sleep, nutrition, screening, and personalized prevention remain the strongest longevity tools available today.
Don't miss
Barzilai’s closing synthesis contrasts experimental rejuvenation approaches with the evidence-based habits and screening that remain most dependable today.
The brief
David Barzilai, a longevity medicine physician and Harvard Medical School lecturer, frames aging as a modifiable biological process rather than an unavoidable list of diseases.
The conversation moves through aging hallmarks, telomere attrition, senescent cells, autophagy, and mitochondria, emphasizing that these systems interact rather than operate independently.
Epigenetic clocks may eventually show whether an intervention slows biological aging, but composite biomarkers and clinical endpoints remain difficult to validate.
Rapamycin, blood-factor research, and Yamanaka-factor reprogramming offer intriguing routes to rejuvenation, yet the most promising results remain experimental and require caution.
Barzilai’s practical conclusion is notably grounded: know personal risk, pursue screening and early detection, and prioritize exercise, sleep, nutrition, and fitness.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.